Chinese scientists have reported that HPV testing on menstrual blood collected with a mini sanitary pad performs about as accurately as clinician-collected cervical sampling, a finding that could reshape cervical-cancer screening and improve participation.
A radical shift: HPV testing at home with a pad
A study recently published in The BMJ by investigators from Zhongnan Hospital of Wuhan University and collaborators validated a noninvasive, privacy-friendly screening model in which women collect menstrual blood at home using a specially designed mini pad and then test it for human papillomavirus, or HPV.
According to the BMJ paper, this is the largest cross-sectional study in the world to assess the accuracy of HPV testing on menstrual blood. It enrolled 3,068 women aged 20 to 54 from multiple locations in Hubei Province.
Each participant completed three tests: menstrual-blood collection using the standardized mini pad at home, HPV molecular testing on that specimen, and clinician-collected cervical sampling followed by HPV testing and liquid-based cytology. The team also introduced technical innovations to improve capture of low-quality samples.
The results were striking. In detecting 14 high-risk HPV types and identifying cervical precancer, the sensitivity and specificity of pad-based sampling were almost equivalent to those of clinician-collected cervical samples. Agreement at the genotype level reached 97.7%.
Home testing could raise screening rates
Cervical cancer is the first cancer the world has a realistic chance to eliminate, yet screening uptake remains insufficient in many places because of cost, time, access, embarrassment, and discomfort associated with conventional gynecologic examination.
The pad-based method is entirely noninvasive and synchronized with a woman's normal menstrual cycle. Because the study included both urban and rural participants, the authors believe it may be especially useful in settings where medical access is limited.
The team also developed a digital mini-program to deliver results and prompt follow-up when the test is positive. Internationally, this work fits with a broader move toward self-sampling for HPV screening.
At the same time, the authors emphasize that menstrual-blood screening cannot yet replace existing cervical-cancer screening methods. Further multicenter validation, biomarker development, and cost-effectiveness analysis are still needed before large-scale implementation can be decided.